287 related articles for article (PubMed ID: 17503348)
21. Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
Rivalland G; Loveland B; Mitchell P
Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294
[TBL] [Abstract][Full Text] [Related]
22. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
23. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
24. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
25. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
26. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Acres B; Lacoste G; Limacher JM
Curr Top Microbiol Immunol; 2017; 405():79-97. PubMed ID: 25702159
[TBL] [Abstract][Full Text] [Related]
27. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
28. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
29. MUC1 as a potential target in anticancer therapies.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Am J Clin Oncol; 2015 Feb; 38(1):108-18. PubMed ID: 23608828
[TBL] [Abstract][Full Text] [Related]
30. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Apostolopoulos V; Pietersz GA; Tsibanis A; Tsikkinis A; Drakaki H; Loveland BE; Piddlesden SJ; Plebanski M; Pouniotis DS; Alexis MN; McKenzie IF; Vassilaros S
Breast Cancer Res; 2006; 8(3):R27. PubMed ID: 16776849
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
32. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
33. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
Ciborowski P; Finn OJ
Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
[TBL] [Abstract][Full Text] [Related]
34. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.
Mukherjee P; Tinder TL; Basu GD; Pathangey LB; Chen L; Gendler SJ
Breast Dis; 2004; 20():53-63. PubMed ID: 15687707
[TBL] [Abstract][Full Text] [Related]
36. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
[TBL] [Abstract][Full Text] [Related]
37. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
38. MUC1 in carcinoma-host interactions.
Denda-Nagai K; Irimura T
Glycoconj J; 2000; 17(7-9):649-58. PubMed ID: 11421355
[TBL] [Abstract][Full Text] [Related]
39. Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis.
Cascio S; Finn OJ
Biomolecules; 2016 Oct; 6(4):. PubMed ID: 27754373
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
